×
About 2,325 results

ALLMedicine™ Immuno-oncology Center

Research & Reviews  881 results

Outcomes of patients with solid tumour malignancies treated with first-line immuno-onco...
https://doi.org/10.1016/j.ejca.2021.04.004
European Journal of Cancer (Oxford, England : 1990); Gan CL, Stukalin I et. al.

May 11th, 2021 - Immuno-oncology (IO)-based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not represented in these trials. We sought to compare the outcomes of trial-ineligible vs. -eligib...

Validation of a targeted next-generation sequencing panel for tumor mutation burden ana...
https://doi.org/10.1016/j.jmoldx.2021.04.008
The Journal of Molecular Diagnostics : JMD; Fenizia F, Alborelli I et. al.

May 8th, 2021 - Tumor mutation burden (TMB) is evaluated as biomarker of response to immunotherapy. Here we present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for TMB calculation .

The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103757
Molecular Medicine (Cambridge, Mass.); Poźniak M, Porębska N et. al.

May 8th, 2021 - Antibody drug conjugates (ADCs) represent one of the most promising approaches in the current immuno-oncology research. The precise delivery of cytotoxic drugs to the cancer cells using ADCs specific for tumor-associated antigens enables sparing t...

Retrospective analysis of real-world treatment patterns and clinical outcomes in patien...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106229
BMC Cancer; Lester J, Escriu C et. al.

May 8th, 2021 - The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical outcomes in aNSCLC ...

PD-L1 and beyond: Immuno-oncology in cytopathology.
https://doi.org/10.1111/cyt.12982
Cytopathology : Official Journal of the British Society F... Iaccarino A, Salatiello M et. al.

May 6th, 2021 - Over the past decade, immunotherapy has emerged as one of the most promising cancer treatments. Several monoclonal antibodies targeting the programmed death 1 (PD-1)/ programmed death ligand-1 (PD-L1) pathway have been integrated into standard-of-...

see more →

Guidelines  13 results

Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?
https://www.frontiersin.org/articles/10.3389/fmed.2019.00244/full
Frontiers in Medicine; Spaas M,et al

Nov 6th, 2019 - For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (RT) have dominated the field of non-small-cell lung cancer (NSCLC). The recent introduction of immunotherapy (IT) in clinical practice, especially s...

2019 Symposium Features Noteworthy Research on Immunotherapy for Cancer
https://www.asco.org/about-asco/press-center/news-releases/2019-symposium-features-noteworthy-research-immunotherapy
Yum,A.

Feb 28th, 2019 - Nine studies exploring a variety of trends and approaches in immuno-oncology, including adaptive cell therapies, immune checkpoint inhibitors, the use of predictive biomarkers, and more, will be presented at the 2019 ASCO-SITC Clinical Immuno-Onco...

2019 ASCO-SITC Clinical Immuno-Oncology Symposium Program
https://immunosym.org/program

Feb 27th, 2019 - Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on the clinical application of scientific advances in immuno-oncology. At the 2019 Symposium, expert faculty will ...

ASCO-SITC Clinical Immuno-Oncology Symposium
https://immunosym.org/

Feb 27th, 2019 - The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting focused on clinical and translational research in immuno-oncology and the implications for clinical care. ​

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
https://www.pnas.org/content/early/2019/01/10/1811067116
Blando,J.,et al

Jan 10th, 2019 - The study demonstrates that V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint that is preferentially expressed at higher levels in pancreatic cancer. The study gives a detailed analysis of immune infiltration ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  1,249 results

Outcomes of patients with solid tumour malignancies treated with first-line immuno-onco...
https://doi.org/10.1016/j.ejca.2021.04.004
European Journal of Cancer (Oxford, England : 1990); Gan CL, Stukalin I et. al.

May 11th, 2021 - Immuno-oncology (IO)-based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not represented in these trials. We sought to compare the outcomes of trial-ineligible vs. -eligib...

Validation of a targeted next-generation sequencing panel for tumor mutation burden ana...
https://doi.org/10.1016/j.jmoldx.2021.04.008
The Journal of Molecular Diagnostics : JMD; Fenizia F, Alborelli I et. al.

May 8th, 2021 - Tumor mutation burden (TMB) is evaluated as biomarker of response to immunotherapy. Here we present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for TMB calculation .

The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103757
Molecular Medicine (Cambridge, Mass.); Poźniak M, Porębska N et. al.

May 8th, 2021 - Antibody drug conjugates (ADCs) represent one of the most promising approaches in the current immuno-oncology research. The precise delivery of cytotoxic drugs to the cancer cells using ADCs specific for tumor-associated antigens enables sparing t...

Retrospective analysis of real-world treatment patterns and clinical outcomes in patien...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106229
BMC Cancer; Lester J, Escriu C et. al.

May 8th, 2021 - The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical outcomes in aNSCLC ...

PD-L1 and beyond: Immuno-oncology in cytopathology.
https://doi.org/10.1111/cyt.12982
Cytopathology : Official Journal of the British Society F... Iaccarino A, Salatiello M et. al.

May 6th, 2021 - Over the past decade, immunotherapy has emerged as one of the most promising cancer treatments. Several monoclonal antibodies targeting the programmed death 1 (PD-1)/ programmed death ligand-1 (PD-L1) pathway have been integrated into standard-of-...

see more →

News  179 results

Studies Back Neoadjuvant Strategies for Melanoma
https://www.medscape.com/viewarticle/947712

Mar 23rd, 2021 - This transcript has been edited for clarity. Hello. I'm Dr Jeffrey Weber. I'm a medical oncologist at the Laura and Isaac Perlmutter Cancer Center here in New York City. Today we're going to talk about neoadjuvant therapy. The February issue of Na...

Lymphopenia linked to worse response in RCC, bladder cancer patients on checkpoint inhibitors
https://www.mdedge.com/hematology-oncology/article/218905/genitourinary-cancer/lymphopenia-linked-worse-response-rcc?channel=39313
Sharon Worcester

Mar 12th, 2020 - ORLANDO – Response to checkpoint inhibitors was associated with pretreatment absolute lymphocyte count (pALC) and neutrophil-lymphocyte ratio (pNLR) in patients with kidney or bladder cancer treated in a real-world setting. Sharon Worcester/MDedge.

Model reveals genes associated with prognosis in ER+, HER2– breast cancer
https://www.mdedge.com/hematology-oncology/article/217154/breast-cancer/model-reveals-genes-associated-prognosis-er-her2?channel=39313
Sharon Worcester

Feb 12th, 2020 - ORLANDO – A machine learning–assisted prognostication model identified genes in the tumor microenvironment that are strongly associated with worse prognosis in patients with stage III, estrogen receptor-positive, HER2-negative breast cancer, accor.

Adding Ilixadencel Improved Outcomes in Metastatic Renal Cell Carcinoma
https://www.staging.medscape.com/viewarticle/925068

Feb 10th, 2020 - ORLANDO, Florida — Combining intratumoral injections of ilixadencel, an off-the-shelf dendritic cell–based primer, with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA...

see more →